Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert Goosmann who wrote (4782)	11/20/1997 11:43:00 AM
From: aknahow	Respond to of 17367

Robert, how could anyone not notice! I am also supprised and disapointed. But I have seen how the Lancet article can have an impact on some. There is obviously a lag between one event and a decision to act on that event. While I always question what is I see, if others do not see it, I find Bob K. is right in that we know more. The Lancet article was after all based on info that has been around for a long time. Apparently it may not have even mentioned the 350 lb factor, of which we were all aware. Yet people that are more "important" to Xomas stock price than we are have just understood the progress made to date as represented by PI/II. As Tharos stated low volume may mean selling has dried up. Holders already know the score and now we must wait for others to make a decision to buy. For the moment perhaps the Lancet article just will get decison makers to put Xoma on their radar screens. In that case the wait will take longer. I really would like to know if it is easier to get a p.r. release picked up if it looks like pure info, i.e. no reference to a co that may be trying to promote itself.

To: Robert Goosmann who wrote (4782)	11/20/1997 11:57:00 AM
From: Maxer	Read Replies (1) \| Respond to of 17367

strange that xoma's trading has all but vanished. I would have thought that the price rise in anticipation of the presentations at the meetings in Europe would have done something more to the price of Xoma shares. I don't know how things are done in the biotech industry, but in many businesses there are accepted ways of working, making deals in a particular way, making presentations to a spacific recognized audiences. Does Xoma follow the patterns of other successful biotechs? Seems it might not, but I really don't know. Comments on this welcome.